Revised: 27 May 2013
Medsafe and the TGA are seeking comments from interested parties on proposed reforms to the business processes for the evaluation of over-the-counter (OTC) medicines.
Document released for consultation on Thursday 13th September 2012
Interested parties should respond by close of business Wednesday 7th November 2012
Feedback will be released following consideration of submissions.
The Australian Therapeutic Goods Administration (TGA) and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) have been working on a review of the business processes for the evaluation of OTC medicines. The objectives of the reforms are to:
This consultation paper outlines the key elements of the proposed business process reforms. The purpose is to seek feedback on the proposed reforms before proceeding with a detailed design of the new business processes, and development of associated documentation, such as regulatory guidelines.
Detailed information on how to make a submission, and who to contact for further information about the proposed reforms, is detailed within the body of the consultation paper.
Please note: Submissions should be confined to the specific subject matter of this consultation paper. Any submissions received that do not directly relate to the subject area, or that reference other consultation papers, will not be considered.
If you wish any information contained in your submission to be treated as confidential, please clearly identify that information and outline the reasons why you consider it to be confidential. Note that general disclaimers in covering emails will not be taken to be sufficient reason for submissions to be treated confidentially.
Manager Product Regulation
Medsafe, Ministry of Health
PO Box 5013
OTC Medicines Regulatory Process Review
Therapeutic Goods Administration
PO Box 100
WODEN ACT 2606
Any questions relating to submissions should be directed to the OTC Medicines Business Process Reform, via email to OTCBPRconsultationpaper@tga.gov.au
In New Zealand:
Any questions relating to submissions should be directed to the Manager Product Regulation, via email to email@example.com
The deadline for receipt of submissions is: 7th November 2012
The period for consultation on the proposed reforms to the business processes for OTC medicines has now closed. Analysis of submissions is currently being undertaken and the outcome of this will be advised on the Medsafe website and the Therapeutic Goods Administration website at www.tga.gov.au as soon as possible. Implementation of the changes is expected to commence in both countries by the end of April 2013.